MONTREAL, May 9, 2006 (PRIMEZONE) -- Viropro Inc. ("Viropro" or "The Company") (OTCBB:VPRO) is rapidly solidifying its reputation as an international expert in the production and set-up of technology transfers of therapeutic proteins to pharmaceutical companies for the treatment of diseases such as cancer, diabetes, hepatitis and multiple sclerosis. The industrial production is destined for emerging regions of the world with unmet needs such as South America, Asia and Africa.
Viropro is entering this vital market with a solid technological platform, an experienced management team in the development of international businesses and an innovative approach in the therapeutic proteins field. By offering its partners integrated solutions and understanding the niche markets it serves, Viropro is positioning itself in a market worth 15 billion dollars U.S. for the 10 biggest selling proteins which no longer have market exclusivity.
With this significant market potential, the company intends to materialize future agreements which will further demonstrate its know-how and technological expertise. Viropro provides pharmaceutical companies access to robust revenues and profitable potential markets. Viropro offers pharmaceutical partners new expertise and new technological platform at a competitive price from which these companies will manufacture and bring to market new therapeutic proteins. It is presently in negotiations with several South American and African pharmaceutical companies with the objective of signing agreements for marketing and technological partnerships in the near future. Announcements on this subject should be made over the coming weeks.
Viropro relies on a business model built on recurring sales revenues and short-term profitability scenario. Viropro intends to maintain a light, flexible and low over-head cost structure by outsourcing services for non-core business activities.
The management has a proven track record with numerous achievements in life sciences and a solid international network built with life science industry leaders, Public, Para-Public and Governmental organizations as well as health and regulatory agencies.
About Viropro Inc.
Viropro Inc. operates mainly through its subsidiary Viropro International Inc. with its Head Office in Montreal, Canada. Viropro is a company specializing in marketing its know-how and expertise in technology transfer for industrial production of therapeutic proteins. Besides today's announcement, Viropro has concluded other strategic alliances with renowned scientific and business partners, both at the national and international levels. Viropro relies on a business model built to generate short and medium term recurrent revenues while increasing the value of stock for both the company and its shareholders.
For more information on Viropro Inc, please visit our website on www.viropro.com
Viropro Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbour created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements." Forward-looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.